The peroxisome proliferator-activated receptor-β/δ antagonist GSK0660 mitigates retinal cell inflammation and leukostasis.

MLA

Capozzi, Megan E., et al. “The Peroxisome Proliferator-Activated Receptor-β/δ Antagonist GSK0660 Mitigates Retinal Cell Inflammation and Leukostasis.” Experimental Eye Research, vol. 190, Jan. 2020, p. 107885. EBSCOhost, https://doi.org/10.1016/j.exer.2019.107885.

APA

Capozzi, M. E., Savage, S. R., McCollum, G. W., Hammer, S. S., Ramos, C. J., Yang, R., Bretz, C. A., & Penn, J. S. (2020). The peroxisome proliferator-activated receptor-β/δ antagonist GSK0660 mitigates retinal cell inflammation and leukostasis. Experimental Eye Research, 190, 107885. https://doi.org/10.1016/j.exer.2019.107885

Chicago

Capozzi, Megan E, Sara R Savage, Gary W McCollum, Sandra S Hammer, Carla J Ramos, Rong Yang, Colin A Bretz, and John S Penn. 2020. “The Peroxisome Proliferator-Activated Receptor-β/δ Antagonist GSK0660 Mitigates Retinal Cell Inflammation and Leukostasis.” Experimental Eye Research 190 (January): 107885. doi:10.1016/j.exer.2019.107885.